Compile Data Set for Download or QSAR
Report error Found 76 Enz. Inhib. hit(s) with all data for entry = 8216
TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237018(US9388197, 20)
Affinity DataIC50: 1.5nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237032(US9388197, 34)
Affinity DataIC50: 1.60nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237039(US9388197, 41)
Affinity DataIC50: 1.80nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237060(US9388197, 62)
Affinity DataIC50: 1.90nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237065(US9388197, 67)
Affinity DataIC50: 2.60nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237063(US9388197, 65)
Affinity DataIC50: 2.70nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237025(US9388197, 27)
Affinity DataIC50: 3nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237072(US9388197, 74)
Affinity DataIC50: 3.90nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237009(US9388197, 11)
Affinity DataIC50: 4.10nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237058(US9388197, 60)
Affinity DataIC50: 4.30nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237004(US9388197, 6)
Affinity DataIC50: 4.30nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237066(US9388197, 68)
Affinity DataIC50: 4.30nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237017(US9388197, 19)
Affinity DataIC50: 4.5nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237026(US9388197, 28)
Affinity DataIC50: 4.70nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237057(US9388197, 59)
Affinity DataIC50: 4.90nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237038(US9388197, 40)
Affinity DataIC50: 5.20nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237023(US9388197, 25)
Affinity DataIC50: 6.30nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237054(US9388197, 56)
Affinity DataIC50: 6.70nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237040(US9388197, 42)
Affinity DataIC50: 6.90nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237003(US9388197, 5)
Affinity DataIC50: 7.30nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237046(US9388197, 48)
Affinity DataIC50: 7.5nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237050(US9388197, 52)
Affinity DataIC50: 7.5nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237052(US9388197, 54)
Affinity DataIC50: 8.90nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237015(US9388197, 17)
Affinity DataIC50: 11nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237008(US9388197, 10)
Affinity DataIC50: 12nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237059(US9388197, 61)
Affinity DataIC50: 12nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237064(US9388197, 66)
Affinity DataIC50: 13nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237051(US9388197, 53)
Affinity DataIC50: 13nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237071(US9388197, 73)
Affinity DataIC50: 13nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237010(US9388197, 12)
Affinity DataIC50: 13nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237013(US9388197, 15)
Affinity DataIC50: 15nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237011(US9388197, 13)
Affinity DataIC50: 17nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237061(US9388197, 63)
Affinity DataIC50: 20nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237048(US9388197, 50)
Affinity DataIC50: 20nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237029(US9388197, 31)
Affinity DataIC50: 22nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237049(US9388197, 51)
Affinity DataIC50: 23nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237047(US9388197, 49)
Affinity DataIC50: 25nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237056(US9388197, 58)
Affinity DataIC50: 31nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237070(US9388197, 72)
Affinity DataIC50: 36nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237012(US9388197, 14)
Affinity DataIC50: 38nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237031(US9388197, 33)
Affinity DataIC50: 44nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237024(US9388197, 26)
Affinity DataIC50: 49nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237041(US9388197, 43)
Affinity DataIC50: 53nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237016(US9388197, 18)
Affinity DataIC50: 66nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237034(US9388197, 36)
Affinity DataIC50: 71nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237030(US9388197, 32)
Affinity DataIC50: 76nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237073(US9388197, 75 | US9388197, 76)
Affinity DataIC50: 82nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237020(US9388197, 22)
Affinity DataIC50: 85nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237022(US9388197, 24)
Affinity DataIC50: 92nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237069(US9388197, 71)
Affinity DataIC50: 94nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

Displayed 1 to 50 (of 76 total ) | Next | Last >>
Jump to: